BACKGROUND: Systematic inflammatory responses such as the elevated @entity1851 , erythrocyte sedimentation rate and lymphocyte-monocyte ratio have been found to have significant prognostic value in @entity1358 ( @entity1358 ). The purpose of this study was to identify the impact of pretherapeutic plasma @entity2002 levels on survival for @entity1358 @entity1 . @entity1 AND METHODS: We retrospectively reviewed 126 @entity1358 @entity1 who were treated at our institution. The median follow-up period was 30.8 months. 116 @entity1 underwent nephrectomy. RESULTS: The 3-year overall survival rates in @entity1 with non-metastatic or metastatic @entity1358 were 91.9% and 14.3%, respectively (p < 0.001). Pretherapeutic plasma @entity2002 levels in the metastatic group were significantly higher than those in the non-metastatic group (p < 0.001). In the non-metastatic group, multivariate analysis revealed that the pathological T stage (p = 0.008), @entity880 dehydrogenase (p = 0.007) and @entity2002 (p = 0.036) were independent prognostic factors for survival. Overall survival rates in @entity1 with low @entity2002 levels (< 399 mg/dl) were significantly higher than in those with high @entity2002 levels (>=  399 mg/dl). CONCLUSION: Pretherapeutic high plasma @entity2002 levels are associated with disease progression in @entity1 with @entity1358 of all stages. We propose that pretherapeutic plasma @entity2002 levels may become a useful biomarker, and could be helpful for decision making in the management of @entity1358 .

Pretherapeutic Plasma @entity2002 Level is an Independent Survival Predictor in XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS'] @entity2002 :: ('2244', 'Gene') :: ['fibrinogen'] @entity1358 :: ('MESH:D002292', 'Disease') :: ['renal cell carcinoma', 'RCC'] @entity880 :: ('MESH:D019344', 'Chemical') :: ['lactate'] @entity1851 :: ('1401', 'Gene') :: ['C-reactive protein']
@entity1358 :: (MESH:D002292,Disease) :: ['Renal Cell Carcinoma']
